Oneness Biotech

4743.TWO

2.23 USD

-0.14

-5.91%

Overview

Last close

2.23 usd

Market cap

1.07B usd

52 week high

5.08 usd

52 week low

1.56 usd

Target price

9.76 usd

Valuation

P/E

N/A

Forward P/E

N/A

Price/Sales

288.7004

Price/Book Value

3.4117

Enterprise Value

959.36M usd

EV/Revenue

258.1423

EV/EBITDA

-91.0869

Key financials

Revenue TTM

3.72M usd

Gross Profit TTM

977351.92 usd

EBITDA TTM

-16.99M usd

Earnings per Share

-0.09 usd

Dividend

N/A usd

Total assets

388.42M usd

Net debt

N/A usd

About

Oneness Biotech Co., Ltd. engages in the research, development, and sale of new drugs, pharmaceuticals, and health products in Taiwan. It offers Fespixon cream for diabetic foot ulcers, and Bonvadis, an innovative wound care medical device. The company develops ON101, which is in Phase III clinical trials for treating chronic diabetic foot ulcers. It is also developing FB825, which is in Phase IIa clinical trial for treating atopic dermatitis and allergic asthma; FB704A that has completed Phase I clinical trial for the treatment of rheumatoid arthritis; SNS812, for the treatment of COVID-19 that is in Phase II clinical trials; and SNS851 for weight loss and metabolism diseases. In addition, the company engages in the management of agriculture cultivation and trading business; and production and sale of agricultural products. Oneness Biotech Co., Ltd. was incorporated in 2008 and is headquartered in Taipei, Taiwan.